Leukaemia Vaccine Cuts Death Risk by 41% in Phase 3 Trial, SELLAS Reports
SELLAS Life Sciences said its experimental cancer vaccine galinpepimut-S extended median survival to 24 months in patients with acute myeloid leukaemia, and the company now plans to seek an accelerated filing with the US Food and Drug Administration.
